BMJ  2008;336:484-487 (1 March), doi:10.1136/bmj.39463.640787.BE (published 4 February 2008)

Research

Long term efficacy of DOTS regimens for tuberculosis: systematic review

¹ Australian International Health Institute, University of Melbourne, Carlton, VIC 3010, Melbourne, Australia

Objective To identify published studies assessing tuberculosis recurrence after successful treatment with standard short course regimens for six months to determine the strength and sufficiency of evidence to support current guidelines.

Design Systematic review.

Data sources Medline, Embase, Cochrane clinical trials register, specialist tuberculosis journals, and reference lists. Only English language publications were eligible.

Review methods Studies were included irrespective of methodology or quality. Abstracted information included inclusion and exclusion criteria for participants, duration of follow-up, and definitions of treatment success and disease recurrence. The primary outcome was the proportion of successfully treated patients recorded with recurrent tuberculosis during the follow-up period.

Results 17 study arms from 16 studies met the inclusion criteria; 10 were controlled clinical trials and six were either studies done under programmatic conditions or observational studies from functioning tuberculosis programmes. Although several clinical trials supported the use of daily treatment regimens, studies reporting tuberculosis recurrence after intermittent regimens were limited. Few studies carried out under routine programmatic conditions reported disease recurrence. Overall there was wide variation in recurrence after successful treatment, ranging from 0% to 14%. Considerable heterogeneity across studies precluded the systematic assessment of factors contributing to tuberculosis recurrence.

Conclusions Despite DOTS (directly observed treatment, short course) being implemented for more than 10 years and millions of patients treated for tuberculosis, few studies have assessed the ability of standard DOTS regimens to result in lasting cure for patients treated under routine programmatic conditions.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Doubts about DOTS

G R Davies and S B Squire
BMJ 2008 336: 457-458. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Verma, R. K., Kaur, J., Kumar, K., Yadav, A. B., Misra, A. (2008). Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice. Antimicrob. Agents Chemother. 52: 3195-3201 [Abstract] [Full text]  
• d'Arc Lyra Batista, J., de Fatima Pessoa Militao de Albuquerque, M., de Alencar Ximenes, R. A., Rodrigues, L. C. (2008). Smoking increases the risk of relapse after successful tuberculosis treatment. Int J Epidemiol 37: 841-851 [Abstract] [Full text]  
• Davies, G R, Squire, S B (2008). Doubts about DOTS. BMJ 336: 457-458 [Full text]  

Rapid Responses:

Read all Rapid Responses

Lesser Evidence for Lesser Mortals in Tuberculosis Treatment

V Murlidhar
bmj.com, 6 Feb 2008 [Full text]

Potential Alternative to Univeral DOT

Thomas S. Moulding
bmj.com, 10 Feb 2008 [Full text]

We must practice DOTS, but we must find better ways to individualise the treatment

Prasanta Raghab Mohapatra, et al.
bmj.com, 12 Feb 2008 [Full text]

DOTS and Democracy

Niyi Awofeso
bmj.com, 13 Feb 2008 [Full text]

DOTS in health care and in public health

T. Jacob John
bmj.com, 13 Feb 2008 [Full text]

All tuberculosis patients need treatment and DOTS today appears feasible though needs further research

R. K. Bansal, et al.
bmj.com, 14 Feb 2008 [Full text]

Early diagnosis in tuberculosis and use of DOT in third world countries

Prof (Dr)Jogenananda Pramanik.MBBS.MD., et al.
bmj.com, 15 Feb 2008 [Full text]

DOTS for some - not all

Raj B SINGH
bmj.com, 17 Feb 2008 [Full text]

DOTS is not the answer for rising incidence of world Tuberculosis.

Chettykulam N. Deivanayagam
bmj.com, 17 Feb 2008 [Full text]

DOTS - a good start

Sourabh Chand
bmj.com, 19 Feb 2008 [Full text]

DOTS-from patient's perspective

R.Karthik Deivanayagam
bmj.com, 20 Feb 2008 [Full text]

Exogenous reinfection as a confounding factor in TB drug trials outcomes.

Paul D van Helden, et al.
bmj.com, 21 Feb 2008 [Full text]

DOTS may be revisited

JAYANTI P GUPTA
bmj.com, 24 Feb 2008 [Full text]

Identify more the work on Tuberculosis from the Indian subcontinent

Jecko Varghese
bmj.com, 1 Mar 2008 [Full text]

It is not the DOTS strategy but direct observation that is failing.

Ibrahim Abubakar, et al.
bmj.com, 4 Mar 2008 [Full text]

I miss a citation

Arild Bjorndal
bmj.com, 5 Mar 2008 [Full text]

DOTS, the baby and the bath water

Alistair Story, et al.
bmj.com, 7 Mar 2008 [Full text]

DOTS is god but certain issues need to be addressed.

Naghman Bashir
bmj.com, 7 Mar 2008 [Full text]

Issues in assessing long-term efficacy of DOTS regimen

Sachin R. Atre, et al.
bmj.com, 8 Mar 2008 [Full text]

Just says there is no good evedence

Kidangazhiyathmana Ajithkumar
bmj.com, 24 Mar 2008 [Full text]

Quality matters in applying standard six-month DOTS regimens under programme conditions

Kwok C Chang, et al.
bmj.com, 27 May 2008 [Full text]